AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6407503 — intervention group
Group type: COMPARATOR
Intervention: Chlorimipramine (50-150 mg daily)
Number of subjects: 73
Study 6407503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (150-300 mg three times daily)
Number of subjects: 73
Study 6407503 — intervention group
Group type: COMPARATOR
Intervention: Chlorimipramine (150-300 mg three times daily)
Number of subjects: 73
Study 6407503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 73
Study 31416344 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 40
Study 31416344 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study 29895378 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-rheumatic treatment (methotrexate monotherapy or anti-TNF therapy with or without methotrexate)
Number of subjects: 130
Study 28391661 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% strontium acetate dentifrice with 1040 ppm fluoride as sodium fluoride
Number of subjects: 135
Study 28391661 — intervention group
Group type: COMPARATOR
Intervention: Commercially available regular fluoride dentifrice containing 1400 ppm fluoride as sodium monofluorophosphate (negative control)
Number of subjects: 135
Study 24103221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation with a single Arctic Front balloon (23 or 28 mm) per patient and two 300-second applications per PV
Number of subjects: 50
Study 24103221 — intervention group
Group type: COMPARATOR
Intervention: Open‐irrigated radiofrequency catheters with Lasso and Navistar ThermoCool catheters and the CARTO system
Number of subjects: 50
Study 24103221 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete PV conduction block at the end of the procedure
Number of subjects: 50
Study 22101200 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-only cardiopulmonary resuscitation (HO-CPR)
Number of subjects: 863
Study 22101200 — intervention group
Group type: COMPARATOR
Intervention: 30:2 cardiopulmonary resuscitation (30:2 CPR)
Number of subjects: 863
Study 20800986 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate (APC) used in ACL reconstruction (group A)
Number of subjects: 50
Study 20800986 — intervention group
Group type: COMPARATOR
Intervention: Control group (no APC used, group B)
Number of subjects: 50
Study 18533739 — intervention group
Group type: EXPERIMENTAL
Intervention: Early GP IIb/IIIa inhibition in patients undergoing PCI for STEMI
Number of subjects: 0
Study 18533739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with fibrinolytics and GP IIb/IIIa inhibitors
Number of subjects: 0
Study 18533739 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 0
Study 18533739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive approach
Number of subjects: 0
Study 17072072 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and endurance training
Number of subjects: 33
Study 17072072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 33
Study 14507107 — intervention group
Group type: EXPERIMENTAL
Intervention: Scholl Flight Socks (14-17 mmHg of pressure at the ankle)
Number of subjects: 224
Study 14507107 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stockings)
Number of subjects: 224
Study 10720541 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, attenuated, cold-adapted, trivalent influenza vaccine administered by nasal spray
Number of subjects: 0
Study 8725709 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step warfarin regimen beginning 10-14 days pre-operatively
Number of subjects: 0
Study 8725709 — intervention group
Group type: COMPARATOR
Intervention: Warfarin beginning the night before surgery
Number of subjects: 0
Study 1559048 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session social learning based AIDS/drug injection prevention program
Number of subjects: 104
Study 1559048 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 104
Study 3889071 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Number of subjects: 16
Study 3889071 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing in conjunction with a gingivectomy procedure
Number of subjects: 16
Study 3889071 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing in conjunction with an apically repositioned flap procedure without bone recontouring
Number of subjects: 16
Study 3889071 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing in conjunction with an apically repositioned flap procedure including bone recontouring
Number of subjects: 16
Study 3889071 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing in conjunction with a modified Widman flap procedure without bone recontouring
Number of subjects: 16
Study 3889071 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing in conjunction with a modified Widman flap procedure including bone recontouring
Number of subjects: 16
Study 30796851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) over 6 months
Number of subjects: 48
Study 30796851 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 48
Study 30796851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) in before-and-after design
Number of subjects: 48
Study 30607117 — intervention group
Group type: EXPERIMENTAL
Intervention: San Huang decoction (shd), taken twice daily for 1 day before surgery and for 7 days postoperatively.
Number of subjects: 30
Study 30607117 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken twice daily for 1 day before surgery and for 7 days postoperatively.
Number of subjects: 30
Study 27501003 — intervention group
Group type: EXPERIMENTAL
Intervention: TORAYLIGHT NV (NV) dialyzer
Number of subjects: 20
Study 27501003 — intervention group
Group type: COMPARATOR
Intervention: Conventional polysulfone (Con) dialyzer
Number of subjects: 20
Study 24597798 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFAs (3.4 g/day EPA and DHA ethyl‐esters)
Number of subjects: 0
Study 22728519 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (MPPT)
Number of subjects: 53
Study 22728519 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy (MPPT) with alendronate
Number of subjects: 53
Study 22728519 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone pulse therapy (MPPT) without alendronate
Number of subjects: 53
Study 20669265 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily extended-release (ER) pramipexole
Number of subjects: 156
Study 20669265 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) pramipexole
Number of subjects: 156
Study 20669265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (ER and IR)
Number of subjects: 156
Study 17963457 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (2004-2005 or 2005-2006)
Number of subjects: 14
Study 17963457 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 healthy volunteers)
Number of subjects: 14
Study 16255010 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/day prednisolone
Number of subjects: 250
Study 16255010 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone
Number of subjects: 250
Study 11097313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacia CAP specific IgE
Number of subjects: 34
Study 11097313 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE to 19‐kDa allergens
Number of subjects: 34
Study 11097313 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE binding to 24‐kDa, 16‐kDa, and 9‐kDa allergens
Number of subjects: 34
Study 11097313 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodate oxidation
Number of subjects: 34
Study 9354308 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmune Neoral and Neoplanta capsules, single dose of 175 mg
Number of subjects: 24
Study 8442966 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic epidural saline (40 to 60 ml)
Number of subjects: 74
Study 8442966 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood (15 ml) via epidural catheter
Number of subjects: 74
Study 8442966 — intervention group
Group type: COMPARATOR
Intervention: Fluids and analgesics (control group)
Number of subjects: 74
Study 3531034 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentonium bromide
Number of subjects: 28
Study 3531034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 28937147 — intervention group
Group type: EXPERIMENTAL
Intervention: Conbercept 0.5 mg
Number of subjects: 180
Study 28937147 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg
Number of subjects: 180
Study 27388878 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention provided by a trained community psychiatric nurse, followed by referral to primary care.
Number of subjects: 0
Study 27388878 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (long-term supportive contacts with a community psychiatric nurse and pharmacological management by a psychiatrist).
Number of subjects: 0
Study 24189763 — intervention group
Group type: EXPERIMENTAL
Intervention: LD-1227
Number of subjects: 76
Study 24189763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 24189763 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 76
Study 21575998 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet replacing saturated fat with monounsaturated fat (MUFA) by adding macadamia nuts
Number of subjects: 64
Study 21575998 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 64
Study 21575998 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet replacing saturated fat with monounsaturated fat (MUFA)
Number of subjects: 64
Study 18499435 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of plain and hyperbaric bupivacaine (5mg each)
Number of subjects: 72
Study 18499435 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine (10mg)
Number of subjects: 72
Study 16599830 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed fruit and vegetable juice powder concentrate, twice daily for 30 days
Number of subjects: 32
Study 16599830 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-smokers)
Number of subjects: 32
Study 14535973 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid therapy
Number of subjects: 182
Study 14535973 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 182
Study 14535973 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma total homocysteine
Number of subjects: 182
Study 11009241 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (40 microg/h) with bupivacaine 0.125% (8 mL/h)
Number of subjects: 24
Study 11009241 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine (without epinephrine)
Number of subjects: 24
Study 11009241 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 24
Study 9284763 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg p.o. 4 h before and 250 mg p.o. 1 h before GHRH
Number of subjects: 14
Study 9284763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1607256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin + Aspirin
Number of subjects: 23
Study 1607256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1607256 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin
Number of subjects: 23
Study 3523718 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP) and Sulfamethoxazole (SMZ) 160 mg/800 mg twice daily for five days
Number of subjects: 37
Study 3523718 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP) 200 mg twice daily for five days
Number of subjects: 37
Study 3523718 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicozamycin 500 mg four times a day for three days
Number of subjects: 37
Study 3523718 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone 100 mg four times a day for five days
Number of subjects: 37
Study 3523718 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for TMP-SMZ and TMP)
Number of subjects: 37
Study 3523718 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for bicozamycin)
Number of subjects: 37
Study 3523718 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for furazolidone and ampicillin)
Number of subjects: 37
Study 29652042 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanotherapeutic system training with VR feedback
Number of subjects: 30
Study 29652042 — intervention group
Group type: COMPARATOR
Intervention: Task-oriented motor training with arm weight support and visual feedback
Number of subjects: 30
Study 27459273 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 50
Study 27459273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 50
Study 25015735 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented red ginseng (FRG), 3 times per day for 4 weeks
Number of subjects: 42
Study 25015735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 22646240 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading dose)
Number of subjects: 20
Study 22646240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20836956 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-visit indirect pulp therapy (IPT)
Number of subjects: 154
Study 20836956 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-visit indirect pulp therapy (IPT)
Number of subjects: 154
Study 20836956 — intervention group
Group type: COMPARATOR
Intervention: Direct complete excavation (DCE)
Number of subjects: 154
Study 18671816 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 6 mg/day
Number of subjects: 138
Study 18671816 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine 2.5 mg/kg/day
Number of subjects: 138
Study 18671816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 20516539 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 183
Study 20516539 — intervention group
Group type: COMPARATOR
Intervention: Cabergoline
Number of subjects: 183
Study 16278786 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (0.2, 0.4, 0.6, or 0.8 microg/kg/day)
Number of subjects: 12
Study 16278786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 12
Study 11897445 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day)
Number of subjects: 22
Study 11897445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9592448 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention in the PACU
Number of subjects: 0
Study 9592448 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 0
Study 7837151 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 16
Study 7837151 — intervention group
Group type: COMPARATOR
Intervention: Control population (not specified)
Number of subjects: 16
Study 3495505 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole as an adjuvant radiosensitizer
Number of subjects: 0
Study 3495505 — intervention group
Group type: COMPARATOR
Intervention: No metronidazole treatment (Control)
Number of subjects: 0
Study 3495505 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole treatment
Number of subjects: 0
Study 30595325 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based surveillance intervention
Number of subjects: 883
Study 30595325 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no school-based surveillance)
Number of subjects: 883
Study 30595325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 883
Study 30595325 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 883
Study 27998277 — intervention group
Group type: EXPERIMENTAL
Intervention: GP training in recovery-oriented practice
Number of subjects: 18
Study 24112306 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus one, two, or three commitment-enhancing BCTs (public self-commitment, implementation intentions, reminders)
Number of subjects: 340
Study 24112306 — intervention group
Group type: COMPARATOR
Intervention: Information only
Number of subjects: 340
Study 22858061 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary posterior continuous curvilinear capsulorrhexis (CCC) with posterior optic buttonholing
Number of subjects: 20
Study 22858061 — intervention group
Group type: COMPARATOR
Intervention: Conventional in‐the‐bag implantation
Number of subjects: 20
Study 20430261 — intervention group
Group type: EXPERIMENTAL
Intervention: rhNRG‐1 (0.6 microg/kg/day)
Number of subjects: 44
Study 20430261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 18495436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone IM 2 mg
Number of subjects: 79
Study 18495436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone IM 20 mg
Number of subjects: 79
Study 18495436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone IM
Number of subjects: 79
Study 16157918 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐B
Number of subjects: 0
Study 16157918 — intervention group
Group type: COMPARATOR
Intervention: BTX‐A
Number of subjects: 0
Study 12944028 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN)
Number of subjects: 14
Study 12944028 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 14
Study 12944028 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine with ISMN
Number of subjects: 14
Study 10535435 — intervention group
Group type: EXPERIMENTAL
Intervention: WCH (White Coat Hypertension) group
Number of subjects: 254
Study 10535435 — intervention group
Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 254
Study 10535435 — intervention group
Group type: EXPERIMENTAL
Intervention: WCH group
Number of subjects: 254
Study 10535435 — intervention group
Group type: EXPERIMENTAL
Intervention: True hypertension group
Number of subjects: 254
Study 8671345 — intervention group
Group type: EXPERIMENTAL
Intervention: Free beta-HCG measurement in threatened-continuing pregnancies
Number of subjects: 554
Study 8671345 — intervention group
Group type: EXPERIMENTAL
Intervention: Free beta-HCG measurement in threatened-miscarriages
Number of subjects: 554
Study 8671345 — intervention group
Group type: EXPERIMENTAL
Intervention: Free beta-HCG measurement in non-continuing pregnancies
Number of subjects: 554
Study 8671345 — intervention group
Group type: EXPERIMENTAL
Intervention: Free beta-HCG measurement in tubal pregnancies
Number of subjects: 554
Study 8671345 — intervention group
Group type: COMPARATOR
Intervention: Free beta-HCG measurement in control group (viable pregnancies)
Number of subjects: 554
Study 8671345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off value for free beta-HCG
Number of subjects: 554
Study 1930351 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder (900 mg total dose)
Number of subjects: 0
Study 1930351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6754508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined frusemide (40 mg) and controlled-release potassium chloride (600 mg)
Number of subjects: 30
Study 6754508 — intervention group
Group type: COMPARATOR
Intervention: Frusemide and potassium supplements given as separate tablets
Number of subjects: 30
Study 28587493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate intake
Number of subjects: 200
Study 28587493 — intervention group
Group type: COMPARATOR
Intervention: Non-bicarbonate group (oxytocin stimulation)
Number of subjects: 200
Study 27372892 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personalized ergonomic intervention program
Number of subjects: 31
Study 27372892 — intervention group
Group type: COMPARATOR
Intervention: Control group (instruction sheets)
Number of subjects: 31
Study 24611924 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol misuse (AUDIT)
Number of subjects: 204
Study 24611924 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR-S drug misuse subscale
Number of subjects: 204
Study 24611924 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR-S substance use disorder (SUD) screening
Number of subjects: 204
Study 24611924 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of education (in model using AUDIT)
Number of subjects: 204
Study 23200208 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program (DMP) for diabetes mellitus type II
Number of subjects: 0
Study 23200208 — intervention group
Group type: COMPARATOR
Intervention: Control group (administrative data)
Number of subjects: 0
Study 20484446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricalcium phosphate
Number of subjects: 211
Study 20484446 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 211
Study 17583416 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening intervention (randomized cohort of 822 men)
Number of subjects: 1769
Study 17583416 — intervention group
Group type: COMPARATOR
Intervention: Clinically diagnosed cohort (nonrandomized cohort of 947 men)
Number of subjects: 1769
Study 15943599 — intervention group
Group type: EXPERIMENTAL
Intervention: AstraZeneca facemask
Number of subjects: 24
Study 15943599 — intervention group
Group type: EXPERIMENTAL
Intervention: Galemed facemask
Number of subjects: 24
Study 15943599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hans Rudolph facemask
Number of subjects: 24
Study 15943599 — intervention group
Group type: EXPERIMENTAL
Intervention: All masks
Number of subjects: 24
Study 15293649 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-couple group therapy
Number of subjects: 42
Study 15293649 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual couple therapy
Number of subjects: 42
Study 15293649 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 42